PATENT CLAIM ANALYSIS

Application Number: 15985106
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "171000"]

Abstract:
A novel combination comprising a 17 α-hydroxylase/C17,20 lyase inhibitor, for example: (3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol or a pharmaceutically acceptable salt or ester thereof, and an AKT inhibitor, for example: N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of 17 α-hydroxylase/C17,20 lyase and/or AKT inhibition is beneficial, e.g., cancer.

Claim (Index 10):
The method of  claim 6 , wherein compound (I) is in the form of the acetate ester and the compound (II) is in the form of the hydrochloride salt.

Metadata:
- Claim Count in Document: 28.0
- Percentile: 93.0
- Lexical Diversity: 1.62121
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15385205', '13500698', '13991576', '13699077', '14456180']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7637396657123393
- 35 USC 102 Novelty (BERT): 0.5193850810791346
- Combined Prediction Score: 0.7393042072490188
- Mean Citation Score: 263.49821000000003
- Max Citation Score: 288.44916
- Similarity Product: 181.52040256227488

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test